Vitamin D and cardiometabolic health: A review of the evidence

Nutrition Research Reviews

Volumn 24, Issue 1, 2011, Pages 1-20

  Muldowney, Siobhan ^a   Kiely, Mairead ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

CVD; Hypertension; Inflammation; Insulin resistance; Metabolic syndrome; Obesity; Type 2 diabetes; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; COLECALCIFEROL; VITAMIN D; 25-HYDROXYVITAMIN D;

ABDOMINAL OBESITY; AGING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; DISEASE PREDISPOSITION; DYSLIPIDEMIA; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; METABOLIC DISORDER; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; ANALOGS AND DERIVATIVES; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; DIET SUPPLEMENTATION; METABOLIC SYNDROME X;

CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; HUMANS; METABOLIC SYNDROME X; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 79958777004     PISSN: 09544224     EISSN: 14752700     Source Type: Journal    
DOI: 10.1017/S0954422410000259     Document Type: Review

References (211)

1. Lloyd-Jones D, Adams R, Carnethon M, et al. (2009) Heart Disease and Stroke Statistics - 2009 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119, e21-e181.
2. Central Statistics Office (2007) Deaths from Principal Causes Registered in the Years 1998 to 2005. Cork, Republic of Ireland: Central Statistics Office.
3. Thom T, Haase N, Rosamond W, et al. (2006) Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113, e85-e151.
4. Yusuf SH, Hawken S, Ounpuu S, et al. (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case - control study. Lancet 364, 937-952. (Pubitemid 39208455)
5. Kylin E (1923) Studien uber das Hypertonie-Hyperglyka 'mie-Hyperurika' Miesyndrom (Studies of the hypertension - hyperglycemia - hyperuricemia syndrome). Zentralbl Inn Med 44, 105-127.
6. Ford ES, Giles WH & Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287, 356-359. (Pubitemid 34251969)
7. Hu G, Qiao Q, Tuomilehto J, et al. (2004) Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 164, 1066-1076. (Pubitemid 38668985)
8. Villegas RP, Perry IJ, Creagh D, et al. (2003) Prevalence of the metabolic syndrome in middle-aged men and women. Diabetes Care 26, 3198-3199. (Pubitemid 37339535)
9. World Health Organization (1999) Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Geneva: Department of Noncommunicable Disease Surveillance.
10. National Institutes of Health (2001) Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Executive Summary. Bethesda, MD: National Institutes of Health.
11. Ford ES, Ajani UA, McGuire LC, et al. (2005) Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Diabetes Care 28, 1228-1230. (Pubitemid 40616645)
12. Dobnig H, Pilz S, Scharnagl H, et al. (2008) Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med 168, 1340-1349. (Pubitemid 351930842)
13. 3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab 93, 677-681.
14. Abdelkefi A, Achour W, Ben Othman T, et al. (2007) Use of heparin-coated central venous lines to prevent catheter-related bloodstream infection. J Support Oncol 5, 273-278. (Pubitemid 46995362)
15. Holick MF (2004) Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 79, 362-371.
16. Haussler MR, Whitfield GK, Haussler CA, et al. (1998) The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 13, 325-349. (Pubitemid 28146215)
17. Zittermann A (2003) Vitamin D in preventive medicine: are we ignoring the evidence? Br J Nutr 89, 552-572.
18. Hass GM, Landerholm W & Hemmens A (1966) Production of calcific athero-arteriosclerosis and thromboarteritis with nicotine, vitamin D and dietary cholesterol. Am J Pathol 49, 739-771.
19. Eisenstein R, Ellis H & Rosato J (1969) In vitro studies of vitamin D-induced aortic calcification. Proc Soc Exp Biol Med 132, 58-62.
20. Morrison LM, Bajwa GS, Alfin-Slater RB, et al. (1972) Prevention of vascular lesions by chondroitin sulfate A in the coronary artery and aorta of rats induced by a hypervitaminosis D, cholesterol-containing diet. Atherosclerosis 16, 105-118.
21. Linden V (1974) Vitamin D and myocardial infarction. Br Med J 3, 647-650.
22. Schmidt-Gayk H, Goossen J, Lendle F, et al. (1977) Serum 25-hydroxycalciferol in myocardial infarction. Atherosclerosis 26, 55-58.
23. Vik B, Try K, Thelle DS, et al. (1979) Tromso Heart Study: vitamin D metabolism and myocardial infarction. Br Med J 2, 176. (Pubitemid 9219912)
24. Zittermann A & Koerfer R (2008) Vitamin D in the prevention and treatment of coronary heart disease. Curr Opin Clin Nutr Metab Care 11, 752-757.
25. Zittermann A, Schleithoff SS & Koerfer R (2005) Putting cardiovascular disease and vitamin D insufficiency into perspective. Br J Nutr 94, 483-492. (Pubitemid 41555486)
26. Grimes DS, Hindle E & Dyer T (1996) Sunlight, cholesterol and coronary heart disease. Q J Med 89, 579-590.
27. Giovannucci E, Liu Y, Hollis BW, et al. (2008) 25-Hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 168, 1174-1180. (Pubitemid 351831400)
28. 3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 326, 469.
29. Hsia J, Heiss G, Ren H, et al. (2007) Calcium/vitamin D supplementation and cardiovascular events. Circulation 115, 846-854. (Pubitemid 46294725)
30. LaCroix AZ, Kotchen J, Anderson G, et al. (2009) Calcium plus vitamin D supplementation and mortality in postmenopausal women: the Women's Health Initiative calcium - vitamin D randomized controlled trial. J Gerontol A Biol Sci Med Sci 64, 559-567.
31. Prince RL, Austin N, Devine A, et al. (2008) Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women. Arch Intern Med 168, 103-108.
32. Bolland MJ, Avenell A, Baron JA, et al. (2010) Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta analysis. BMJ 341, c3691.
33. Alberti KG, Zimmet P & Shaw J (2005) The metabolic syndrome - a new worldwide definition. Lancet 366, 1059-1062. (Pubitemid 41338752)
34. Einhorn D, Reaven GM, Cobin RH, et al. (2003) American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 9, 237-252.
35. Grundy SM, Cleeman JI, Daniels SR, et al. (2005) Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev 13, 322-327.
36. Isomaa B, Almgren P, Tuomi T, et al. (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24, 683-689. (Pubitemid 32893993)
37. Forouhi NG, Luan J, Cooper A, et al. (2008) Baseline serum 25-hydroxy vitamin D is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990-2000. Diabetes 57, 2619-2625.
38. Hypponen E, Boucher BJ, Berry DJ, et al. (2008) 25-Hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: a cross-sectional study in the 1958 British Birth Cohort. Diabetes 57, 298-305.
39. Reis JP, von Muhlen D & Miller ER III (2008) Relation of 25- hydroxyvitamin D and parathyroid hormone levels with metabolic syndrome among US adults. Eur J Endocrinol 159, 41-48. (Pubitemid 351969129)
40. Hjelmesaeth J, Hofso D, Aasheim ET, et al. (2009) Parathyroid hormone, but not vitamin D, is associated with the metabolic syndrome in morbidly obese women and men: a cross-sectional study. Cardiovasc Diabetol 8, 7.
41. 3 with anthropometry and markers of the metabolic syndrome and diabetes in overweight and obesity. Nutr J 7, 4.
42. Reis JP, von Muhlen D, Kritz-Silverstein D, et al. (2007) Vitamin D, parathyroid hormone levels, and the prevalence of metabolic syndrome in community-dwelling older adults. Diabetes Care 30, 1549-1555. (Pubitemid 46871169)
43. Parker J, Hashmi O, Dutton D, et al. (2010) Levels of vitamin D and cardiometabolic disorders: systematic review and meta-analysis. Maturitas 65, 225-236.
44. Weyer C, Bogardus C & Pratley RE (1999) Metabolic factors contributing to increased resting metabolic rate and decreased insulin-induced thermogenesis during the development of type 2 diabetes. Diabetes 48, 1607-1614. (Pubitemid 29356870)
45. Pittas AG, Lau J, Hu FB, et al. (2007) The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 92, 2017-2029. (Pubitemid 46997093)
46. Teegarden D & Donkin SS (2009) Vitamin D: emerging new roles in insulin sensitivity. Nutr Res Rev 22, 82-92.
47. 3-1α-hydroxylase in pancreatic islets. J Steroid Biochem Mol Biol 89-90, 121-125.
48. Zeitz U, Weber K, Soegiarto DW, et al. (2003) Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J 17, 509-511.
49. 3 on de novo insulin biosynthesis in the islets of the rat endocrine pancreas. J Endocrinol 160, 87-95.
50. Arnold BM, Kuttner M, Swaminathan R, et al. (1975) Radioimmunoassay studies of intestinal calcium-binding protein in the pig. I. Identification of intestinal calcium-binding protein in blood and response to a low calcium diet. Can J Physiol Pharmacol 53, 1129-1134.
51. Morrissey RL, Bucci TJ, Richard B, et al. (1975) Calciumbinding protein: its cellular localization in jejunum, kidney and pancreas. Proc Soc Exp Biol Med 149, 56-60.
52. 28k knockout mice and b cell lines. J Biol Chem 274, 34343-34349.
53. Chiu KC, Chu A, Go VL, et al. (2004) Hypovitaminosis D is associated with insulin resistance and β cell dysfunction. Am J Clin Nutr 79, 820-825. (Pubitemid 41103882)
54. 3 on insulin receptor gene expression, insulin receptor number and insulin activity in the kidney, liver and adipose tissue of streptozotocin- induced diabetic rats. BMC Mol Biol 9, 65.
55. Chiu KC, Chuang LM, Lee NP, et al. (2000) Insulin sensitivity is inversely correlated with plasma intact parathyroid hormone level. Metabolism 49, 1501-1505.
56. McCarty MF & Thomas CA (2003) PTH excess may promote weight gain by impeding catecholamine-induced lipolysis - implications for the impact of calcium, vitamin D, and alcohol on body weight. Med Hypotheses 61, 535-542. (Pubitemid 37411898)
57. Wareham NJ, Byrne CD, Carr C, et al. (1997) Glucose intolerance is associated with altered calcium homeostasis: a possible link between increased serum calcium concentration and cardiovascular disease mortality. Metabolism 46, 1171-1177. (Pubitemid 27418507)
58. Snijder M, van Dam R, Visser M, et al. (2006) To: Mathieu C, Gysemans C, Giulietti A, Bouillon R (2005) Vitamin D and diabetes. Diabetologia 48, 1247-1257. Diabetologia 49, 217-218.
59. Reis AF, Hauache OM & Velho G (2005) Vitamin D endocrine system and the genetic susceptibility to diabetes, obesity and vascular disease. A review of evidence. Diabetes Metab 31, 318-325. (Pubitemid 41391473)
60. Palomer X, Gonzalez-Clemente JM, Blanco-Vaca F, et al. (2008) Role of vitamin D in the pathogenesis of type 2 diabetes mellitus. Diabetes Obes Metab 10, 185-197. (Pubitemid 351249776)
61. Dilmec F, Uzer E, Akkafa F, et al. (2010) Detection of VDR gene ApaI and TaqI polymorphisms in patients with type 2 diabetes mellitus using PCR-RFLP method in a Turkish population. J Diabetes Complications 24, 186-191.
62. Ye WZ, Dubois-Laforgue D, Bellanne-Chantelot C, et al. (2001) Variations in the vitamin D-binding protein (Gc locus) and risk of type 2 diabetes mellitus in French Caucasians. Metabolism 50, 366-369. (Pubitemid 32248987)
63. Malecki MT, Frey J, Moczulski D, et al. (2003) Vitamin D receptor gene polymorphisms and association with type 2 diabetes mellitus in a Polish population. Exp Clin Endocrinol Diabetes 111, 505-509. (Pubitemid 38101497)
64. Hitman GA, Mannan N, McDermott MF, et al. (1998) Vitamin D receptor gene polymorphisms influence insulin secretion in Bangladeshi Asians. Diabetes 47, 688-690. (Pubitemid 28160463)
65. Ogunkolade BW, Boucher BJ, Prahl JM, et al. (2002) Vitamin Dreceptor (VDR) mRNA and VDR protein levels in relation to vitamin D status, insulin secretory capacity, and VDR genotype in Bangladeshi Asians. Diabetes 51, 2294-2300. (Pubitemid 34729038)
66. Oh JY & Barrett-Connor E (2002) Association between vitamin D receptor polymorphism and type 2 diabetes or metabolic syndrome in community-dwelling older adults: the Rancho Bernardo Study. Metabolism 51, 356-359.
67. Tworowska-Bardzinska U, Lwow F, Kubicka E, et al. (2008) The vitamin D receptor gene BsmI polymorphism is not associated with anthropometric and biochemical parameters describing metabolic syndrome in postmenopausal women. Gynecol Endocrinol 24, 514-518.
68. Chiu KC, Chuang LM & Yoon C (2001) The vitamin D receptor polymorphism in the translation initiation codon is a risk factor for insulin resistance in glucose tolerant Caucasians. BMC Med Genet 2, 2.
69. Filus A, Trzmiel A, Kuliczkowska-Plaksej J, et al. (2008) Relationship between vitaminDreceptor BsmI and FokI polymorphisms and anthropometric and biochemical parameters describing metabolic syndrome. Aging Male 11, 134-139.
70. Tai K, Need AG, Horowitz M, et al. (2008) Vitamin D, glucose, insulin, and insulin sensitivity. Nutrition 24, 279-285.
71. Timms PM, Mannan N, Hitman GA, et al. (2002) Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM 95, 787-796.
72. Duncan BB, Schmidt MI, Pankow JS, et al. (2003) Lowgrade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 52, 1799-1805. (Pubitemid 36792473)
73. Pradhan AD, Manson JE, Rifai N, et al. (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286, 327-334. (Pubitemid 32656163)
74. Giulietti A, van Etten E, Overbergh L, et al. (2007) Monocytes from type 2 diabetic patients have a pro-inflammatory profile. 1,25-Dihydroxyvitamin D3 works as anti-inflammatory. Diabetes Res Clin Pract 77, 47-57. (Pubitemid 46590467)
75. Choi HK, Willett WC, Stampfer MJ, et al. (2005) Dairy consumption and risk of type 2 diabetes mellitus in men: a prospective study. Arch Intern Med 165, 997-1003. (Pubitemid 40638119)
76. Liu S, Song Y, Ford ES, et al. (2005) Dietary calcium, vitamin D, and the prevalence of metabolic syndrome in middleaged and older U.S. women. Diabetes Care 28, 2926-2932. (Pubitemid 43942926)
77. Liu S, Choi HK, Ford E, et al. (2006) A prospective study of dairy intake and the risk of type 2 diabetes in women. Diabetes Care 29, 1579-1584. (Pubitemid 44127584)
78. Pittas AG, Dawson-Hughes B, Li T, et al. (2006) Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care 29, 650-656. (Pubitemid 44115368)
79. Scragg R, Sowers M & Bell C (2004) Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 27, 2813-2818. (Pubitemid 39565042)
80. Liu E, Meigs JB, Pittas AG, et al. (2009) Plasma 25-hydroxyvitamin D is associated with markers of the insulin resistant phenotype in nondiabetic adults. J Nutr 139, 329-334.
81. 3 levels decreased in impaired glucose tolerance and diabetes mellitus. Diabetes Res Clin Pract 27, 181-188.
82. Hypponen E & Power C (2006) Vitamin D status and glucose homeostasis in the 1958 British birth cohort: the role of obesity. Diabetes Care 29, 2244-2246. (Pubitemid 44899859)
83. 3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. Diabet Med 26, 19-27.
84. 3 on insulin secretion and peripheral insulin sensitivity in type 2 diabetic patients. Int J Clin Pract 57, 258-261.
85. von Hurst PR, Stonehouse W & Coad J (2010) Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient - a randomised, placebocontrolled trial. Br J Nutr 103, 549-555.
86. Jorde R & Figenschau Y (2009) Supplementation with cholecalciferol does not improve glycaemic control in diabetic subjects with normal serum 25-hydroxyvitamin D levels. Eur J Nutr 48, 349-354.
87. Pittas AG, Harris SS, Stark PC, et al. (2007) The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care 30, 980-986. (Pubitemid 46556596)
88. Dawson-Hughes B, Harris SS, Krall EA, et al. (1997) Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337, 670-676. (Pubitemid 27375473)
89. 3 for 1 year. J Intern Med 267, 462-472.
90. de Boer IH, Tinker LF, Connelly S, et al. (2008) Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women's Health Initiative. Diabetes Care 31, 701-707.
91. World Health Organization (2006) Obesity and Overweight. Fact sheet no. 311. http://www.who.int/mediacentre/factsheets/fs311/en/index.html (accessed November 2008).
92. Flegal KM, Carroll MD, Ogden CL, et al. (2002) Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288, 1723-1727.
93. McCarthy SN, Harrington KE, Kiely M, et al. (2001) Analyses of the anthropometric data from the North/South Ireland Food Consumption Survey. Public Health Nutr 4, 1099-1106. (Pubitemid 33014943)
94. Lee P & Cunningham K (1990) The Irish National Nutrition Survey. Dublin: Irish Nutrition and Dietetic Institute.
95. Pérez-López F (2009) Vitamin D metabolism and cardiovascular risk factors in postmenopausal women. Maturitas 62, 248-262.
96. Jorde R, Sneve M, Emaus N, et al. (2010) Cross-sectional and longitudinal relation between serum 25-hydroxyvitamin D and body mass index: the Tromso study. Eur J Nutr 49, 401-407.
97. Compston JE, Vedi S, Ledger JE, et al. (1981) Vitamin D status and bone histomorphometry in gross obesity. Am J Clin Nutr 34, 2359-2363. (Pubitemid 12176062)
98. Harris SS & Dawson-Hughes B (2007) Reduced sun exposure does not explain the inverse association of 25-hydroxyvitamin D with percent body fat in older adults. J Clin Endocrinol Metab 92, 3155-3157. (Pubitemid 47236385)
99. Bell NH, Epstein S, Greene A, et al. (1985) Evidence for alteration of the vitamin D - endocrine system in obese subjects. J Clin Invest 76, 370-373. (Pubitemid 15243466)
100. 3 modulates human adipocyte metabolism via nongenomic action. FASEB J 15, 2751-2753.
101. Zemel MB, Shi H, Greer B, et al. (2000) Regulation of adiposity by dietary calcium. FASEB J 14, 1132-1138. (Pubitemid 30350395)
102. Parikh SJ, Edelman M, Uwaifo GI, et al. (2004) The relationship between obesity and serum 1,25-dihydroxy vitamin D concentrations in healthy adults. J Clin Endocrinol Metab 89, 1196-1199. (Pubitemid 38368412)
103. Konradsen S, Ag H, Lindberg F, et al. (2008) Serum 1,25-dihydroxy vitamin D is inversely associated with body mass index. Eur J Nutr 47, 87-91.
104. Wortsman J, Matsuoka LY, Chen TC, et al. (2000) Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 72, 690-693. (Pubitemid 30667088)
105. Arunabh S, Pollack S, Yeh J, et al. (2003) Body fat content and 25-hydroxyvitamin D levels in healthy women. J Clin Endocrinol Metab 88, 157-161. (Pubitemid 36115158)
106. Freedman BI, Wagenknecht LE, Hairston KG, et al. (2010) Vitamin D, adiposity, and calcified atherosclerotic plaque in African-Americans. J Clin Endocrinol Metab 95, 1076-1083.
107. Sneve M, Figenschau Y & Jorde R (2008) Supplementation with cholecalciferol does not result in weight reduction in overweight and obese subjects. Eur J Endocrinol 159, 675-684.
108. Caan B, Neuhouser M, Aragaki A, et al. (2007) Calcium plus vitamin D supplementation and the risk of postmenopausal weight gain. Arch Intern Med 167, 893-902. (Pubitemid 46762751)
109. Major GC, Alarie F, Dore J, et al. (2007) Supplementation with calcium + vitamin D enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations. Am J Clin Nutr 85, 54-59. (Pubitemid 46067615)
110. Major GC, Alarie FP, Dore J, et al. (2009) Calcium plus vitamin D supplementation and fat mass loss in female very low-calcium consumers: potential link with a calciumspecific appetite control. Br J Nutr 101, 659-663.
111. Zittermann A, Frisch S, Berthold HK, et al. (2009) Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am J Clin Nutr 89, 1321-1327.
112. Chobanian AV, Bakris GL, Black HR, et al. (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289, 2560-2572. (Pubitemid 37430158)
113. Wang Y & Wang QJ (2004) The prevalence of prehypertension and hypertension among US adults according to the new Joint National Committee guidelines: new challenges of the old problem. Arch Intern Med 164, 2126-2134. (Pubitemid 39410802)
114. Morgan K, McGee H, Watson D, et al (2008) SLÁN 2007, Survey of Lifestyle, Attitudes & Nutrition in Ireland. Main Report. Dublin: Department of Health and Children.
115. Pilz S, Tomaschitz A, Ritz E, et al. (2009) Vitamin D status and arterial hypertension: a systematic review. Nat Rev Cardiol 6, 621-630.
116. Ballermann BJ & Marsden PA (1991) Endothelium-derived vasoactive mediators and renal glomerular function. Clin Invest Med 14, 508-517.
117. Resnick LM, Muller FB & Laragh JH (1986) Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism. Ann Intern Med 105, 649-654.
118. 3 is a negative endocrine regulator of the renin - angiotensin system. J Clin Invest 110, 229-238.
119. Xiang W, Kong J, Chen S, et al. (2005) Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin - angiotensin systems. Am J Physiol Endocrinol Metab 288, E125-E132. (Pubitemid 40023798)
120. Kong J, Qiao G, Zhang Z, et al. (2008) Targeted vitamin D receptor expression in juxtaglomerular cells suppresses renin expression independent of parathyroid hormone and calcium. Kidney Int 74, 1577-1581.
121. 3-dependent regulation of the renin-angiotensin system in 1α-hydroxylase knockout mice. Kidney Int 74, 170-179.
122. 3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 282, 29821-29830.
123. Zemel M (2001) Calcium modulation of hypertension and obesity: mechanisms and implications. J Am Coll Nutr 20, 428-435.
124. Perkovic V, Hewitson TD, Kelynack KJ, et al. (2003) Parathyroid hormone has a prosclerotic effect on vascular smooth muscle cells. Kidney Blood Press Res 26, 27-33. (Pubitemid 36438798)
125. Rostand SG (1997) Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension 30, 150-156.
126. Krause R, Buhring M, Hopfenmuller W, et al. (1998) Ultraviolet B and blood pressure. Lancet 352, 709-710. (Pubitemid 28398716)
127. Sowers MR, Wallace RB & Lemke JH (1985) The association of intakes of vitamin D and calcium with blood pressure among women. Am J Clin Nutr 42, 135-142. (Pubitemid 15028533)
128. Jorde R & Bonaa KH (2000) Calcium from dairy products, vitamin D intake, and blood pressure: the Tromso Study. Am J Clin Nutr 71, 1530-1535. (Pubitemid 30395901)
129. Forman JP, Bischoff-Ferrari HA, Willett WC, et al. (2005) Vitamin D intake and risk of incident hypertension: results from three large prospective cohort studies. Hypertension 46, 676-682. (Pubitemid 43186738)
130. Wang L, Manson JE, Buring JE, et al. (2008) Dietary intake of dairy products, calcium, and vitamin D and the risk of hypertension in middle-aged and older women. Hypertension 51, 1073-1079. (Pubitemid 351398988)
131. Pasco JA, Henry MJ, Nicholson GC, et al. (2009) Behavioural and physical characteristics associated with vitamin D status in women. Bone 44, 1085-1091.
132. Snijder MB, Lips P, Seidell JC, et al. (2007) Vitamin D status and parathyroid hormone levels in relation to blood pressure: a population-based study in older men and women. J Intern Med 261, 558-565. (Pubitemid 46835978)
133. Jorde R, Figenschau Y, Emaus N, et al. (2010) Serum 25-hydroxyvitamin D levels are strongly related to systolic blood pressure but do not predict future hypertension. Hypertension 55, 792-798.
134. Scragg R, Sowers M & Bell C (2007) Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens 20, 713-719. (Pubitemid 46936167)
135. Judd SE, Nanes MS, Ziegler TR, et al. (2008) Optimal vitamin D status attenuates the age-associated increase in systolic blood pressure in white Americans: results from the third National Health and Nutrition Examination Survey. Am J Clin Nutr 87, 136-141.
136. Martins D, Wolf M, Pan D, et al. (2007) Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 167, 1159-1165. (Pubitemid 46919818)
137. Forman JP, Giovannucci E, Holmes MD, et al. (2007) Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 49, 1063-1069. (Pubitemid 351664326)
138. Forman JP, Curhan GC & Taylor EN (2008) Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. Hypertension 52, 828-832.
139. 3 supplementation on cardiovascular risk factors in elderly adults. Eur J Clin Nutr 49, 640-646.
140. Orwoll ES & Oviatt S (1990) Relationship of mineral metabolism and long-term calcium and cholecalciferol supplementation to blood pressure in normotensive men. Am J Clin Nutr 52, 717-721.
141. Margolis KL, Ray RM, Van Horn L, et al. (2008) Effect of calcium and vitamin D supplementation on blood pressure: the Women's Health Initiative Randomized Trial. Hypertension 52, 847-855.
142. 3 and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 86, 1633-1637.
143. Cox RA & Garcia-Palmieri MR (1990) Cholesterol, triglycerides, and associated lipoproteins. In Clinical Methods: The History, Physical and Laboratory Examinations, 3rd ed., Chapter 31, pp. 153-160 [HK Walker, WD Hall and JW Hurst, editors]. Stoneham, MA: Butterworth Publishers.
144. Tziomalos K, Athyros VG, Wierzbicki AS, et al. (2009) Lipoprotein a: where are we now? Curr Opin Cardiol 24, 351-357.
145. Ballantyne C, Arroll B & Shepherd J (2005) Lipids and CVD management: towards a global consensus. Eur Heart J 26, 2224-2231. (Pubitemid 41541384)
146. Kendrick J, Targher G, Smits G, et al. (2009) 25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey. Atherosclerosis 205, 255-260.
147. Bostom AG, Cupples LA, Jenner JL, et al. (1996) Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA 276, 544-548. (Pubitemid 26272299)
148. Hopkins PN, Hunt SC, Schreiner PJ, et al. (1998) Lipoprotein(a) interactions with lipid and non-lipid risk factors in patients with early onset coronary artery disease: results from the NHLBI Family Heart Study. Atherosclerosis 141, 333-345. (Pubitemid 28539641)
149. Barger-Lux MJ, Heaney RP, Lanspa SJ, et al. (1995) An investigation of sources of variation in calcium absorption efficiency. J Clin Endocrinol Metab 80, 406-411.
150. Denke MA, Fox MM & Schulte MC (1993) Short-term dietary calcium fortification increases fecal saturated fat content and reduces serum lipids in men. J Nutr 123, 1047-1053. (Pubitemid 23175940)
151. Reid IR (2004) Effects of calcium supplementation on circulating lipids: potential pharmacoeconomic implications. Drugs Aging 21, 7-17.
152. Vaskonen T, Mervaala E, Sumuvuori V, et al. (2002) Effects of calcium and plant sterols on serum lipids in obese Zucker rats on a low-fat diet. Br J Nutr 87, 239-245. (Pubitemid 34295976)
153. 2+ on the activation of microsomal triglyceride transfer protein in rat hepatocytes. Biol Pharm Bull 28, 1418-1423.
154. Lacour B, Basile C, Drueke T, et al. (1982) Parathyroid function and lipid metabolism in the rat. Miner Electrolyte Metab 7, 157-165. (Pubitemid 12118779)
155. Kelly GS (2005) Seasonal variations of selected cardiovascular risk factors. Altern Med Rev 10, 307-320.
156. Cigolini M, Iagulli MP, Miconi V, et al. (2006) Serum 25-hydroxyvitamin D3 concentrations and prevalence of cardiovascular disease among type 2 diabetic patients. Diabetes Care 29, 722-724. (Pubitemid 44115386)
157. Auwerx J, Bouillon R & Kesteloot H (1992) Relation between
158. Carbone LD, Rosenberg EW, Tolley EA, et al. (2008) 25-Hydroxyvitamin D, cholesterol, and ultraviolet irradiation. Metabolism 57, 741-748.
159. John WG, Noonan K, Mannan N, et al. (2005) Hypovitaminosis D is associated with reductions in serum apolipoprotein A-I but not with fasting lipids in British Bangladeshis. Am J Clin Nutr 82, 517-522.
160. Wang TJ, Pencina MJ, Booth SL, et al. (2008) Vitamin D deficiency and risk of cardiovascular disease. Circulation 117, 503-511.
161. Andersen R, Brot C, Mejborn H, et al. (2009) Vitamin D supplementation does not affect serum lipids and lipoproteins in Pakistani immigrants. Eur J Clin Nutr 63, 1150-1153.
162. Gannage-Yared MH, Azoury M, Mansour I, et al. (2003) Effects of a short-term calcium and vitamin D treatment on serum cytokines, bone markers, insulin and lipid concentrations in healthy post-menopausal women. J Endocrinol Invest 26, 748-753. (Pubitemid 37451753)
163. Rajpathak SN, Xue X, Wassertheil-Smoller S, et al. (2010) Effect of 5 y of calcium plus vitamin D supplementation on change in circulating lipids: results from the Women's Health Initiative. Am J Clin Nutr 91, 894-899.
164. 3 fortified milk on blood pressure and serum lipid concentrations in healthy older men. Eur J Clin Nutr 63, 993-1000.
165. Osmancevic A, Nilsen LT, Landin-Wilhelmsen K, et al. (2009) Effect of climate therapy at Gran Canaria on vitamin D production, blood glucose and lipids in patients with psoriasis. J Eur Acad Dermatol Venereol 23, 1133-1140.
166. 3. Maturitas 22, 55-61.
167. 3 supplementation may have adverse effects on serum lipids during postmenopausal hormone replacement therapy. Eur J Endocrinol 137, 495-502.
168. Wang JH, Keisala T, Solakivi T, et al. (2009) Serum cholesterol and expression of ApoAI, LXRb and SREBP2 in vitamin D receptor knock-out mice. J Steroid Biochem Mol Biol 113, 222-226.
169. Wehmeier K, Beers A, Haas MJ, et al. (2005) Inhibition of apolipoprotein AI gene expression by 1, 25-dihydroxyvitamin D3. Biochim Biophys Acta 1737, 16-26. (Pubitemid 41550379)
170. Kowalska I, Straczkowski M, Nikolajuk A, et al. (2008) Insulin resistance, serum adiponectin, and proinflammatory markers in young subjects with the metabolic syndrome. Metabolism 57, 1539-1544.
171. Libby P (2002) Inflammation in atherosclerosis. Nature 420, 868-874.
172. Libby P, Ridker PM & Maseri A (2002) Inflammation and atherosclerosis. Circulation 105, 1135-1143. (Pubitemid 34212626)
173. Stentz FB, Umpierrez GE, Cuervo R, et al. (2004) Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes 53, 2079-2086. (Pubitemid 38970758)
174. Moore K, de Waal Malefyt R, Coffman R, et al. (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19, 683-765. (Pubitemid 32368050)
175. Festa A, D'Agostino R Jr, Howard G, et al. (2000) Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102, 42.
176. Ridker PM, Buring JE, Cook NR, et al. (2003) C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 107, 391-397.
177. Adams JS & Hewison M (2008) Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab 4, 80-90. (Pubitemid 351156900)
178. 3, and the immune system. Am J Clin Nutr 80, 1717S-1720S.
179. Herder C, Baumert J, Thorand B, et al. (2006) Chemokines as risk factors for type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984-2002. Diabetologia 49, 921-929.
180. Deluca HF & Cantorna MT (2001) Vitamin D: its role and uses in immunology. FASEB J 15, 2579-2585. (Pubitemid 33131084)
181. 3 analogs as immunomodulatory agents. Trends Mol Med 8, 174-179.
182. Overbergh L, Decallonne B, Valckx D, et al. (2000) Identification and immune regulation of 25-hydroxyvitamin D-1-α-hydroxylase in murine macrophages. Clin Exp Immunol 120, 139.
183. 3: basic concepts. J Steroid Biochem Mol Biol 97, 93-101.
184. van Etten E, Stoffels K, Gysemans C, et al. (2008) Regulation of vitamin D homeostasis: implications for the immune system. Nutr Rev 66, Suppl. 2, 125-134.
185. 3 target the TNF-α pathway to suppress experimental inflammatory bowel disease. Eur J Immunol 35, 217-224.
186. 2+: a mediator of endothelial inflammation. Nephrol Dial Transplant 24, 3306-3312.
187. Greenfield EM, Gornik SA, Horowitz MC, et al. (1993) Regulation of cytokine expression in osteoblasts by parathyroid hormone: rapid stimulation of interleukin-6 and leukemia inhibitory factor mRNA. J Bone Miner Res 8, 1163-1171. (Pubitemid 23308109)
188. Shea M, Booth S, Massaro J, et al. (2007) Vitamin K and vitamin D status: associations with inflammatory markers in the Framingham Offspring Study. Am J Epidemiol 167, 313-320.
189. Peterson C & Heffernan M (2008) Serum tumor necrosis factor-α concentrations are negatively correlated with serum 25 (OH) D concentrations in healthy women. J Inflamm (Lond) 5, 10.
190. Van den Berghe G, Van Roosbroeck D, Vanhove P, et al. (2003) Bone turnover in prolonged critical illness: effect of vitamin D. J Clin Endocrinol Metab 88, 4623-4632. (Pubitemid 37357503)
191. Schleithoff SS, Zittermann A, Tenderich G, et al. (2006) Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 83, 754-759. (Pubitemid 44713136)
192. Mahon B, Gordon S, Cruz J, et al. (2003) Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J Neuroimmunol 134, 128-132. (Pubitemid 36050838)
193. Jorde R, Sneve M, Torjesen PA, et al. (2010) No effect of supplementation with cholecalciferol on cytokines and markers of inflammation in overweight and obese subjects. Cytokine 50, 175-180.
194. Weinreich T, Wuthrich RP, Booy C, et al. (2001) Suppression of ICAM-1 expression in renal proximal tubular cells by 1,25-dihydroxyvitamin D3. Kidney Blood Press Res 24, 92-98. (Pubitemid 32642061)
195. 3 inhibits tumor necrosis factor-α-induced adhesion molecule expression in endothelial cells. Cell Biol Int 30, 365-375.
196. 3 decreased ICAM-1 and ELAM-1 expressions on pulmonary microvascular endothelial cells and neutrophil motivation. J Steroid Biochem Mol Biol 52, 67-70.
197. Kreft B, Brzoska S, Doehn C, et al. (1996) 1,25-Dihydroxycholecalciferol enhances the expression of MHC class II antigens and intercellular adhesion molecule-1 by human renal tubular epithelial cells. J Urol 155, 1448-1453. (Pubitemid 26081271)
198. Kohler HP & Grant PJ (2000) Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 342, 1792-1801. (Pubitemid 30390240)
199. Thogersen A, Jansson J, Boman K, et al. (1998) High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98, 2241.
200. Hamsten A, Wiman B, de Faire U, et al. (1985) Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 313, 1557-1563. (Pubitemid 16177394)
201. Hamsten A, de Faire U, Walldius G, et al. (1987) Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet ii, 3-9. (Pubitemid 17083665)
202. Wu-Wong JR, Nakane M & Ma J (2007) Vitamin D analogs modulate the expression of plasminogen activator inhibitor- 1, thrombospondin-1 and thrombomodulin in human aortic smooth muscle cells. J Vasc Res 44, 11-18. (Pubitemid 46105689)
203. Wu-Wong JR, Nakane M, Ma J, et al. (2006) Effects of vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells. Atherosclerosis 186, 20-28.
204. Vaughan DE, Lazos SA & Tong K (1995) Angiotensin II regulates the expression of plasminogen activator inhibitor- 1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 95, 995-1001.
205. Brown NJ, Agirbasli M & Vaughan DE (1999) Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension 34, 285-290. (Pubitemid 29409229)
206. Jorde R, Sneve M, Torjesen P, et al. (2010) Parameters of the thrombogram are associated with serum 25-hydroxyvitamin D levels at baseline, but not affected during supplementation with vitamin D. Thromb Res 125, e210-e213.
207. Rahman A, Hershey S, Ahmed S, et al. (2007) Heart extracellular matrix gene expression profile in the vitamin D receptor knockout mice. J Steroid Biochem Mol Biol 103, 416-419. (Pubitemid 46415673)
208. Dollery C & Libby P (2006) Atherosclerosis and proteinase activation. Cardiovasc Res 69, 625.
209. Dean D, Schwartz Z, Schmitz J, et al. (1996) Vitamin D regulation of metalloproteinase activity in matrix vesicles. Connect Tissue Res 35, 331-336. (Pubitemid 27118865)
210. Tai K, Need AG, Horowitz M, et al. (2008) Glucose tolerance and vitamin D: effects of treating vitamin D deficiency. Nutrition 24, 950-956.
211. Raghuramulu N, Raghunath M, Chandra S, et al. (1992) Vitamin D improves oral glucose tolerance and insulin secretion in human diabetes. J Clin Biochem Nutr 13, 45-51.